Apr 14, 2008
This Podcast for the Neurology Journal begins with Dr. John H. Noseworthy, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Peter Goadsby and Dr. Stephen Silberstein interview Dr. Tony Ho from Merck & Co., Inc. about his paper on oral CGRP antagonist, MK-0974, in acute treatment of migraine. The podcast concludes with Dr. Myla Goldman interviewing Dr. Bruce Levin for Lesson of the Week. The participants had nothing to disclose except for Dr. Silberstein. His Author Disclosure is as follows: Income for speaking, consulting or serving on an advisory board- GlaxoSmithKline, Allergan, AstraZeneca, Endo, Medtronic, Merck, J&J, Pfizer, Pozen, Valeant Pharmaceuticals International (not in excess of $10,000) & Research Support- Allergan (not in excess of $10,000).